MCL1 and B-cell chronic lymphocytic leukemia: Given the remarkable clinical success of the Bcl-2 specific inhibitor, venetoclax or venclaxta, in treating relapsed or refractory chronic lymphocytic leukemia (CLL), many have sought to develop a Mcl-1 specific inhibitor.